Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Last Updated
Case Status
Pending
Federal Trade Commission, Plaintiff, v. Golden Sunrise Nutraceutical, Inc., a corporation; Golden Sunrise Pharmaceutical, Inc., a corporation; Huu Tieu, individually and as an officer of Golden Sunrise Nutraceutical, Inc. and Golden Sunrise Pharmaceutical, Inc.; and Stephen Meis, individually and as an officer of Golden Sunrise Nutraceutical, Inc.; Defendants.
FTC Matter/File Number
202 3146
X200051
Civil Action Number
1:20-at-00540
Enforcement Type
Federal Injunctions
Federal Court
Eastern District of California

Case Summary

In July 2020, the Federal Trade Commission filed a complaint in federal court against the California-based marketers and promoters of bogus treatments for serious medical conditions.  The defendants are two corporations headquartered in Porterville, California, and two of their executives: Huu Tieu, President and CEO of both companies; and Stephen Meis, Medical Director and board member of Golden Sunrise Nutraceutical.  The complaint alleges that defendants have promoted and sold a variety of products through "plans of care" ranging in price from $23,000 to $200,000, which falsely claim to treat or cure COVID-19, cancer, Parkinson's disease, etc. On June 14, 2021, the FTC announced a proposed order barring the defendants from making bogus health claims.